Sanofi (NASDAQ:SNY – Get Free Report)’s share price hit a new 52-week low during mid-day trading on Monday . The company traded as low as $42.78 and last traded at $42.8140, with a volume of 2598798 shares traded. The stock had previously closed at $43.31.
Analyst Upgrades and Downgrades
SNY has been the subject of several research reports. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research report on Thursday, March 19th. UBS Group reaffirmed a “neutral” rating on shares of Sanofi in a research report on Friday, January 16th. BNP Paribas Exane lowered Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective for the company. in a research note on Monday, April 20th. Argus upgraded Sanofi to a “strong-buy” rating in a research note on Monday, April 27th. Finally, Wall Street Zen lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. Two investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $51.00.
Get Our Latest Stock Analysis on Sanofi
Sanofi Stock Down 1.0%
Sanofi Increases Dividend
The firm also recently announced an annual dividend, which will be paid on Wednesday, June 3rd. Stockholders of record on Monday, May 4th will be paid a $2.4225 dividend. This represents a dividend yield of 559.0%. This is a boost from Sanofi’s previous annual dividend of $2.04. The ex-dividend date is Monday, May 4th. Sanofi’s dividend payout ratio is 49.44%.
Institutional Trading of Sanofi
Hedge funds and other institutional investors have recently made changes to their positions in the business. Flagship Harbor Advisors LLC acquired a new stake in shares of Sanofi in the fourth quarter valued at $25,000. Physician Wealth Advisors Inc. increased its stake in shares of Sanofi by 180.5% in the first quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company’s stock valued at $28,000 after buying an additional 379 shares in the last quarter. Leonteq Securities AG increased its stake in shares of Sanofi by 95.8% in the first quarter. Leonteq Securities AG now owns 607 shares of the company’s stock valued at $29,000 after buying an additional 297 shares in the last quarter. Measured Wealth Private Client Group LLC acquired a new stake in shares of Sanofi in the third quarter valued at $29,000. Finally, Palisade Asset Management LLC acquired a new stake in shares of Sanofi in the third quarter valued at $30,000. 14.03% of the stock is currently owned by institutional investors and hedge funds.
About Sanofi
Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.
Key commercial offerings include specialty biologics and established small-molecule medicines.
Featured Stories
- Five stocks we like better than Sanofi
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.
